185 related articles for article (PubMed ID: 26037901)
1. Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
Tran AQ; Cohen JG; Li AJ
Gynecol Oncol; 2015 Aug; 138(2):263-6. PubMed ID: 26037901
[TBL] [Abstract][Full Text] [Related]
2. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.
Cohen JG; Tran AQ; Rimel BJ; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2014 Mar; 132(3):556-9. PubMed ID: 24423879
[TBL] [Abstract][Full Text] [Related]
3. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
4. The impact of body weight on ovarian cancer outcomes.
Backes FJ; Nagel CI; Bussewitz E; Donner J; Hade E; Salani R
Int J Gynecol Cancer; 2011 Dec; 21(9):1601-5. PubMed ID: 21997171
[TBL] [Abstract][Full Text] [Related]
5. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
[TBL] [Abstract][Full Text] [Related]
7. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
8. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
9. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
10. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers.
Goto T; Takano M; Watanabe A; Miyamoto M; Kato M; Hirata J; Sasa H; Furuya K
Int J Gynecol Cancer; 2011 Feb; 21(2):263-8. PubMed ID: 21270609
[TBL] [Abstract][Full Text] [Related]
11. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
[TBL] [Abstract][Full Text] [Related]
12. The effect of obesity on survival in patients with ovarian cancer.
Matthews KS; Straughn JM; Kemper MK; Hoskins KE; Wang W; Rocconi RP
Gynecol Oncol; 2009 Feb; 112(2):389-93. PubMed ID: 19062080
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
14. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
15. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
Lee CK; Lord S; Grunewald T; Gebski V; Hardy-Bessard AC; Sehouli J; Woie K; Heywood M; Schauer C; Vergote I; Scambia G; Ferrero A; Harter P; Pujade-Lauraine E; Friedlander M
Gynecol Oncol; 2015 Jan; 136(1):18-24. PubMed ID: 25281492
[TBL] [Abstract][Full Text] [Related]
16. Impact of beta blockers on epithelial ovarian cancer survival.
Diaz ES; Karlan BY; Li AJ
Gynecol Oncol; 2012 Nov; 127(2):375-8. PubMed ID: 22819786
[TBL] [Abstract][Full Text] [Related]
17. Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
Petrillo M; Amadio G; Salutari V; Paris I; Di Stefano MG; Ferandina G; Scambia G; Fagotti A
Gynecol Oncol; 2016 Aug; 142(2):231-6. PubMed ID: 27215633
[TBL] [Abstract][Full Text] [Related]
18. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
Milam MR; Tao X; Coleman RL; Harrell R; Bassett R; Dos Reis R; Ramirez PT
Int J Gynecol Cancer; 2011 Jan; 21(1):66-71. PubMed ID: 21178571
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
